Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
3rd January 2025 Uncategorised 0As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have been quietly simmering in the background. More: Novo asks FDA to
read more